Molecular Partners AG (MOLN) Price & Analysis

Compare

0 Followers

MOLN Stock Chart & Stats

CHF3.37

-CHF0.06(-1.31%)

At close: Mar 06 4:00 PM EST

CHF3.37

-CHF0.06(-1.31%)

Day’s Range― - ―

52-Week RangeCHF2.70 - CHF5.10

Previous CloseN/A

Volume298.00

Average Volume (3M)17.77K

Market Cap

CHF144.54M

Enterprise ValueCHF3.27M

Total Cash (Recent Filing)CHF104.52M

Total Debt (Recent Filing)CHF1.53M

Price to Earnings (P/E)―

Beta0.38

Next Earnings

Mar 12, 2026

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding40,374,640

10 Day Avg. Volume21,556

30 Day Avg. Volume17,775

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)0.98

Price to Sales (P/S)27.80

P/FCF Ratio-2.30

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF3.00

Price Target Upside-10.98% Downside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial Performance2024 revenue of CHF 5MM and non-GAAP loss per share of CHF 1.59 was better than expected.

Financial PositionThe company has a solid cash position and building momentum behind innovative pipeline programs with broad potential.

Pipeline DevelopmentKey programs are on track, with MP0533 dosing in cohort 9 of its Phase I AML trial ongoing and cohort 10 being planned.

Bears Say

Workforce ReductionA workforce reduction program is being implemented.

Molecular Partners AG News

Molecular Partners forms Scientific Advisory Board

Molecular Partners (MOLN) announced the formation of a Scientific Advisory Board for its radiopharmaceuticals, chaired by Prof. Ken...

9d ago

MOLN

Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan

JPMorgan lowered the firm’s price target on Molecular Partners (MLLCF) to CHF 3 from CHF 3.50 and keeps...

12d ago

MOLN

Molecular Partners price target lowered to $3.75 from $4 at JPMorgan

JPMorgan analyst Richard Vosser lowered the firm’s price target on Molecular Partners (MLLCF) to $3.75 from $4 and...

12d ago

MOLN

Molecular Partners presents updated data from Phase 1/2a trial of MP0533

Molecular Partners (MOLN) has announced it will present updated data from a Phase 1/2a trial of the multispecific...

13d ago

MOLN

Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners

Molecular Partners, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Zhu from...

12d ago

MOLN

Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Molecular Partners. The associated price target...

1M ago

MOLN

Molecular Partners presents new MP0712 data

Molecular Partners (MOLN) announced the presentation of new data on MP0712, its Radio-DARPin targeting DLL3, at the Targeted...

1M ago

MOLN

Molecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Molecular Partners. The associated price target...

2M ago

MOLN

Molecular Partners price target lowered to $4 from $4.50 at JPMorgan

JPMorgan analyst Richard Vosser lowered the firm’s price target on Molecular Partners (MOLN) to $4 from $4.50 and...

4M ago

MOLN

Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on MOLN stock, giving a Buy rating on...

4M ago

MOLN

Promising Developments and Strategic Resource Management Justify Buy Rating for Molecular Partners AG

Analyst Michael Nedelcovych of TD Cowen maintained a Buy rating on Molecular Partners AG, with a price target...

4M ago

MOLN

Molecular Partners Reports H1 2025 Progress and Financial Stability

Molecular Partners ( ($MLLCF) ) has released its Q2 earnings. Here is a breakdown of the information Molecular...

4M ago

Molecular Partners’ Promising Pipeline and Strategic Advancements Justify Buy Rating

Molecular Partners, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Zhu from...

4M ago

MOLN

Molecular Partners appoints Martin Steegmaier as chief scientific officer

Molecular Partners (MOLN) announced the appointment of Martin Steegmaier as chief scientific officer and member of the company’s...

4M ago

MOLN

MOLN FAQ

What was Molecular Partners AG’s price range in the past 12 months?

Molecular Partners AG lowest stock price was CHF2.70 and its highest was CHF5.10 in the past 12 months.

What is Molecular Partners AG’s market cap?

Molecular Partners AG’s market cap is CHF144.54M.

When is Molecular Partners AG’s upcoming earnings report date?

Molecular Partners AG’s upcoming earnings report date is Mar 12, 2026 which is in 82 days.

How were Molecular Partners AG’s earnings last quarter?

Molecular Partners AG released its earnings results on Aug 25, 2025. The company reported -CHF0.55 earnings per share for the quarter, missing the consensus estimate of -CHF0.39 by -CHF0.16.

Is Molecular Partners AG overvalued?

According to Wall Street analysts Molecular Partners AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Molecular Partners AG pay dividends?

Molecular Partners AG does not currently pay dividends.

What is Molecular Partners AG’s EPS estimate?

Molecular Partners AG’s EPS estimate is -0.31.

How many shares outstanding does Molecular Partners AG have?

Molecular Partners AG has 40,374,640 shares outstanding.

What happened to Molecular Partners AG’s price movement after its last earnings report?

Molecular Partners AG reported an EPS of -CHF0.55 in its last earnings report, missing expectations of -CHF0.39. Following the earnings report the stock price went up 0.687%.

Which hedge fund is a major shareholder of Molecular Partners AG?

Currently, no hedge funds are holding shares in CH:MOLN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Molecular Partners AG

Molecular Partners AG (MOLN) is a biotechnology company based in Switzerland that specializes in the development of innovative therapies using its proprietary DARPins (designed ankyrin repeat proteins) technology platform. The company focuses on creating targeted therapeutics for various diseases, particularly in oncology and ophthalmology. Its core products include a pipeline of therapeutic candidates that leverage DARPins to selectively bind to disease targets, enhancing the efficacy and safety of treatments.

Molecular Partners AG (MOLN) Earnings & Revenues

Historic Earnings Reports

MOLN Stock 12 Month Forecast

Average Price Target

CHF3.00

▼(-10.98% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"CHF1","6":"CHF6","2.25":"CHF2.25","3.5":"CHF3.5","4.75":"CHF4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.075,3.0692307692307694,3.0634615384615387,3.057692307692308,3.051923076923077,3.0461538461538464,3.0403846153846157,3.0346153846153845,3.0288461538461537,3.023076923076923,3.0173076923076922,3.0115384615384615,3.0057692307692307,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.075,3.0692307692307694,3.0634615384615387,3.057692307692308,3.051923076923077,3.0461538461538464,3.0403846153846157,3.0346153846153845,3.0288461538461537,3.023076923076923,3.0173076923076922,3.0115384615384615,3.0057692307692307,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.075,3.0692307692307694,3.0634615384615387,3.057692307692308,3.051923076923077,3.0461538461538464,3.0403846153846157,3.0346153846153845,3.0288461538461537,3.023076923076923,3.0173076923076922,3.0115384615384615,3.0057692307692307,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.675,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.285,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.985,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.075,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >